Press Releases in 2010

Check out the latest press releases from Novus. For direct media requests, contact us at
View Press Releases From: 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007

Novus Biologicals Adds Cdx1 to Antibody Catalog

Release Date: 
Wednesday, December 29, 2010 - 07:00

Novus Biologicals recently announced a new rabbit polyclonal anti-Cdx1 antibody (catalog number NBP1-49538).  This Cdx1 antibody was developed using SDIX's Genomic Antibody TechnologyTM (GATTM) and Cdx1 antibodies are applicable for chromatin and epigenetics research.

AmideBio to Present at TIDES Conference

Release Date: 
Friday, December 24, 2010 - 07:00

AmideBio announced today that Dr. Michael Stowell, Chief Technology Officer for AmideBio, will present at TIDES Conference (Oligonucleotide and Peptide® Technology and Product Development). Novus Biologicals is the exclusive worldwide distributor of AmideBio's unique peptides.

Abnova Foray into the In Vitro Dianostic Market

Release Date: 
Friday, December 17, 2010 - 07:00

The movement toward personalized medicine has created an increased market demand for biomarkers which can detect early sign of disease, assess disease prognosis, predict treatment outcome, and manages disease activity. With a strong foothold in antibody manufacturing and antibody-based system integration in profiling and quantification, Abnova, a company for which Novus Biologicals distributes, has made a seamless transition and foray into the in vitro diagnostic (IVD) market.

Lightning-Link Antibody Labeling Kits Positively Reviewed by Researchers

Release Date: 
Thursday, December 9, 2010 - 07:00

Lightning-LinkTM Antibody Labeling Kits, distributed by Novus Biologicals, are the easiest antibody labeling tool available to help you directly label your primary antibody.  Lightning Link kits require only 30 seconds of hands on time and antibody recovery is 100%. Novus provides over 40 different labels to which you can easily label your antibody, including enzymes such as HRP, fluorescent proteins like R-Phycoerythrin, biotin, and tandem labels like PE/Cy5.

New ApoE4 specific antibody from Novus Biologicals

Release Date: 
Wednesday, December 8, 2010 - 07:00

New ApoE4 specific antibody from Novus Biologicals

Apolipoprotein E4 (ApoE4) is one of the three major isoforms of Apolipoprotein E (ApoE).  Antibodies are made to target each of the three major isoforms of ApoE, including ApoE2, ApoE3, and ApoE4.  Novus Biologicals announced a new antibody specific to ApoE4 this week.  This ApoE4-specific antibody (catalog # NBP1-49529) is useful for the study of coronary artery disease and Alzheimer's Disease.

New THAP11 Antibody from Novus Biologicals

Release Date: 
Tuesday, December 7, 2010 - 07:00

Novus Biologicals just announced a new THAP11 antibody (catalog # NBP1-49463).  THAP11 antibodies, also known as Thanatos-associated protein 11 antibodies, are useful for cancer studies and stem cell research.  THAP-11 is a regulator of embryonic stem cells and is in the same field as Oct4, Sox2 and Nanog.

Novus Biologicals adds STMN2 antibody to antibody catalog

Release Date: 
Monday, December 6, 2010 - 07:00

Novus Biologicals recently announced a new primary antibody to STMN2. STMN2, also known as SCG10 and Stathmin 2, is a neuronal growth-associated protein.  This anti-STMN2 antibody is provided as whole antiserum and is available in two sizes (50uL: NBP1-49461 and 25uL: NBP1-49461SS).

New STRO-1 Antibody Announced by Novus Biologicals

Release Date: 
Monday, October 25, 2010 - 06:00

STRO-1 is a stromal cell surface marker that is useful for stem cell research.

Novus Biologicals announces new CCR2 Antibodies

Release Date: 
Monday, October 18, 2010 - 06:00

Novus Biologicals recently introduced two antibodies to C C chemokine receptor type 2 (CCR2).  CCR2 is a regulator of monocyte/macrophage trafficking and is upregulated in response to inflammation. The ligand for CCR2 is monocyte chemoattractant protein (MCP-1), a chemokine produced by endothelial cells, smooth muscle cells, and macrophages. Furthermore, resistance to HIV-1 infection or delayed progression to AIDS may be linked to CCR2 polymorphisms.

Novus Biologicals introduces new LDHA Antibody

Release Date: 
Thursday, October 14, 2010 - 06:00

Novus Biologicals recently introduced an antibody to Lactate dehydrogenase A (LDHA).  LDHA is involved in the final step of anaerobic glycoysis and catalyzes the conversion of L-lactate and NAD to pryruvate and NADH. Novus' new rabbit polyclonal anti-LDHA antibody (catalog # NBP1-48336) was made within residues 300-375 of the human LDHA protein.